TRAIL联用化疗药物抗妇科肿瘤的研究进展

Study progress of TRAIL combined with chemotherapeutics on gynecologic tumor

肿瘤坏死因子相关凋亡诱导配体(TRAIL)因其选择性诱导肿瘤细胞凋亡的特点而受到关注。目前,TRAIL及其受体已被广泛运用于妇科肿瘤的治疗研究中,不同的妇科肿瘤细胞株对TRAIL诱导的凋亡敏感性不同,某些细胞株对TRAIL耐药。克服肿瘤细胞对TRAIL的耐药,同时保护正常细胞免受伤害,

Close attention is paid to selective killing of tumor cells induced by TNF related apoptosis induced ligand （TRAIL） without significant systemic cell toxicity. More and more studies of TRAIL and TRAIL-R focus on its therapeutical effects of gynecologic tumor. Various gynecologic tumor cell lines show different sensibility to TRAIL induces apoptosis. Several cell lines show resistance to TRAIL. To solve the drug resistance of tumor cells and protect the normal cells will bring the virtue of TRAIL which can kill tumor cell without systemic cell toxicity into full play on tumor therapy.